XORTX Therapeutics Inc. is a biopharmaceutical company with three clinically advanced products in development – XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), XRx-101 for Coronavirus / COVID-19 infection and XRx-221, under a letter of intent to establish a co-development program with Teijin Pharma Limited, for Type 2 Diabetic Nephropathy (T2DN). The Company has strong intellectual property rights and established proof of concept through independent clinical studies. XORTX is working to advance its clinical development stage products that target xanthine oxidase to inhibit production of uric acid. At XORTX Therapeutics, we are dedicated to developing medications to improve the quality of life and future of patients.


Media and Videos

Scroll with arrows for additional content


Press Releases

XORTX Announces Notice to Grant European Patent

Patent Supporting Diabetic Nephropathy – XRx-221 April 06, 2021 07:00 ET | Source: XORTX Therapeutics Inc. XORTX Therapeutics Inc. Calgary, Alberta, CANADA CALGARY, Alberta, April 06, 2021 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE: XRX) (OTCQB: XRTXF), a biopharmaceutical company focused on developing therapeutics for the ...
Read More

Receive Press Releases by email

Please enable the javascript to submit this form

Investor Relations

Fact Sheet

Presentation

Read More